ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 175 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q1 2020. The put-call ratio across all filers is 0.92 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $1,096 | -99.7% | 27,326 | +158.8% | 0.11% | +86.2% |
| Q3 2022 | $437,000 | -65.3% | 10,560 | -39.1% | 0.06% | -65.7% |
| Q1 2022 | $1,260,000 | -28.5% | 17,345 | -17.2% | 0.17% | -23.5% |
| Q4 2021 | $1,762,000 | +312.6% | 20,950 | +579.3% | 0.22% | +215.7% |
| Q4 2020 | $427,000 | -1.4% | 3,084 | -69.6% | 0.07% | +40.0% |
| Q4 2019 | $433,000 | +27.4% | 10,129 | +27.3% | 0.05% | +8.7% |
| Q3 2019 | $340,000 | +69.2% | 7,959 | +174.4% | 0.05% | +130.0% |
| Q1 2019 | $201,000 | -75.3% | 2,900 | -72.6% | 0.02% | -50.0% |
| Q2 2018 | $813,000 | -9.4% | 10,582 | -39.9% | 0.04% | -14.9% |
| Q1 2018 | $897,000 | -28.5% | 17,600 | +57.3% | 0.05% | -23.0% |
| Q4 2015 | $1,255,000 | +30.7% | 11,188 | +12.2% | 0.06% | +29.8% |
| Q3 2015 | $960,000 | +6.5% | 9,970 | +13.3% | 0.05% | +34.3% |
| Q2 2015 | $901,000 | +184.2% | 8,800 | +72.5% | 0.04% | +169.2% |
| Q1 2015 | $317,000 | -32.8% | 5,100 | -52.5% | 0.01% | -60.6% |
| Q4 2014 | $472,000 | – | 10,748 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 38,100 | $2,928,000 | 1.67% |
| Opaleye Management Inc. | 80,000 | $6,149,000 | 1.59% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 410,000 | $31,517,000 | 1.06% |
| Opus Point Partners Management, LLC | 6,311 | $485,000 | 1.05% |
| SECTOR GAMMA AS | 68,015 | $5,228,000 | 0.87% |
| Capital Impact Advisors, LLC | 27,074 | $2,061,000 | 0.76% |
| FORTALEZA ASSET MANAGEMENT INC/ | 1,130 | $87,000 | 0.71% |
| CAPITAL INTERNATIONAL LTD /CA/ | 46,957 | $3,610,000 | 0.63% |
| Virtus ETF Advisers LLC | 8,794 | $676,000 | 0.60% |
| Rock Springs Capital Management LP | 200,000 | $15,374,000 | 0.59% |